Skip to main content
  • Loading metrics

The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination

  • Peter J. Hotez , (PJH); (SKA)

    Affiliation Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University and Sabin Vaccine Institute, Washington, D.C., United States of America

  • Maria Elena Bottazzi,

    Affiliation Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University and Sabin Vaccine Institute, Washington, D.C., United States of America

  • Carlos Franco-Paredes,

    Affiliations Hospital Infantil de México, Federico Gómez, México, D.F., México, Department of Medicine, Emory University, Atlanta, Georgia, United States of America

  • Steven K. Ault , (PJH); (SKA)

    Affiliation Pan American Health Organization/World Health Organization (PAHO/WHO), Washington, D.C., United States of America

  • Mirta Roses Periago

    Affiliation Pan American Health Organization/World Health Organization (PAHO/WHO), Washington, D.C., United States of America


The neglected tropical diseases (NTDs) represent some of the most common infections of the poorest people living in the Latin American and Caribbean region (LAC). Because they primarily afflict the disenfranchised poor as well as selected indigenous populations and people of African descent, the NTDs in LAC are largely forgotten diseases even though their collective disease burden may exceed better known conditions such as of HIV/AIDS, tuberculosis, or malaria. Based on their prevalence and healthy life years lost from disability, hookworm infection, other soil-transmitted helminth infections, and Chagas disease are the most important NTDs in LAC, followed by dengue, schistosomiasis, leishmaniasis, trachoma, leprosy, and lymphatic filariasis. On the other hand, for some important NTDs, such as leptospirosis and cysticercosis, complete disease burden estimates are not available. The NTDs in LAC geographically concentrate in 11 different sub-regions, each with a distinctive human and environmental ecology. In the coming years, schistosomiasis could be eliminated in the Caribbean and transmission of lymphatic filariasis and onchocerciasis could be eliminated in Latin America. However, the highest disease burden NTDs, such as Chagas disease, soil-transmitted helminth infections, and hookworm and schistosomiasis co-infections, may first require scale-up of existing resources or the development of new control tools in order to achieve control or elimination. Ultimately, the roadmap for the control and elimination of the more widespread NTDs will require an inter-sectoral approach that bridges public health, social services, and environmental interventions.

The Neglected Tropical Diseases in the Latin American and the Caribbean Region

The neglected tropical diseases (NTDs), a group of chronic, debilitating, and poverty-promoting parasitic, bacterial, and some viral and fungal infections, are among the most common causes of illness of the poorest people living in developing countries [1]. Their control and elimination is now recognized as a priority for achieving United Nations Millennium Development Goals (MDGs) and targets for sustainable poverty reduction [1][3]. Approximately 40% of the estimated 556 million people living in the Latin American and the Caribbean region (LAC) live below the poverty line, including 47 million people who live on less than US$1 per day, and another 74 million people who live on less than US$2 per day [4],[5]. Relative to sub-Saharan Africa and Asia, where NTDs also occur, the character of poverty in LAC is unique. In terms of income distribution, LAC exhibits the highest inequality anywhere [6], with the richest one-tenth of the population earning 48% of total income and the poorest tenth earning only 1.6% [7]. Of LAC's estimated 213 million impoverished people, approximately one-third live in rural poverty as subsistence farmers, ranchers, and fishermen [8], typically in communities of indigenous and African descent where they face a high level of social exclusion and social inequity [9], including lack of access to safe water and health care services [10],[11]. Two-thirds of the region's poor live in favelas, asentamientos pobres, barrios pobres, turgurias, and áreas periféricas, i.e., urban and peri-urban communities where poverty combines with the conditions of unsafe water, poor sanitation, and the proliferation of rodent animal reservoirs and vectors [8],[12].

Poverty is not the only major determinant for risk of acquiring NTDs in LAC. Instead, it combines with other inequities related to ethnicity (e.g., indigenous groups and people of African descent), age and gender (i.e., children and women), and a patchwork of unique ecological niches to establish sometimes highly focal epidemiological NTD “hot spots.” This has important implications for the control of NTDs in LAC, which may differ from the integrated NTD control currently being advocated for and tested in sub-Saharan Africa and elsewhere [1]. Here, we focus on some of the unique aspects of NTD disease burden and endemicity in the LAC region, as well as the prospects for NTD control and elimination in the region. The review of the literature was conducted using the online database PubMed from 2000 to 2007 with United States National Library of Medicine Medical Subject Headings, the specific diseases listed as neglected tropical diseases on the PLoS Neglected Tropical Diseases Web site (, and the geographic regions and countries of LAC. Reference lists of identified articles and reviews were also hand searched as were databases from the Pan American Health Organization (PAHO) Web site (

Burden and Geographic Distribution of Disease

The NTDs in LAC may be characterized by two major patterns of disease distribution. The first is a pattern of widespread endemicity such as that seen for the soil-transmitted helminth (STH) infections, Chagas disease, and dengue; the second pattern is one of geographically restricted endemicity as the result of concerted public health interventions and ecological conditions as seen for onchocerciasis, lymphatic filariasis (LF), and schistosomiasis in areas such as the Caribbean and Guyana shield. The latter group may represent a distinct situation from other parts of the world, as they may be said to represent a “last stronghold” of endemic focal communicable diseases, that can be eliminated in a region but are not yet. In this sense, the presence of such NTDs represents a moral burden as well as an epidemiological burden. Because they are seen by some as illustrations of the failure of primary health care implementation [13], the NTDs also represent a moral imperative for action to complete primary health care implementation where it has failed and make it accessible to all.

Ault [8] previously listed the major NTDs in LAC, and Table 1 ranks these NTDs by their estimated prevalence, at-risk population, and distribution, while Tables 2 and 3 rank the NTDs by their estimated disease burdens measured in disability-adjusted life years (DALYs). The major STH infections are the most prevalent NTDs, and the STH infections and Chagas disease are responsible for the highest estimated NTD burden in LAC. They are followed by dengue, schistosomiasis, leishmaniasis, and other NTDs. However, dengue is considered underreported in the LAC region [14], and because leishmaniasis frequently occurs in remote areas or regions of guerilla conflict [15], its disease burden is not well established except in some areas of Brazil, Peru, and Bolivia [16]. Based on global disease burden estimates in DALYs published previously by the World Health Organization (WHO) and other investigators [17],[18], a range of estimates for NTDs in LAC is provided in Table 2. Such DALY estimates were obtained by adjusting the global estimates according to the percentage of the disease burden determined to occur in LAC, or in some cases they were quoted directly from WHO estimates (Table 2). From this analysis it was determined that the total burden of these NTDs in LAC may exceed the disease burdens from malaria or tuberculosis, and according to some estimates, the regional NTD disease burden exceeds that of HIV/AIDS (Table 2). There are also a number of other important NTDs in LAC (many of which are zoonoses) for which the disease burdens as expressed in DALYs have not been determined or reported (Table 3).

Table 1. Ranking of NTDs in LAC by Prevalence and Distribution.

Table 2. Ranking of NTDs by Disease Burden (DALYs) and Comparison with HIV/AIDS, Tuberculosis, and Malaria.

Table 3. Major NTDs with No National or Regional Disease Burden Estimates in DALYs.

Helminth infections.

The major helminth infections in LAC include Necator americanus hookworm infection and other STH infections, schistosomiasis, LF, cysticercosis, and onchocerciasis. Trichuriasis (100 million cases) and ascariasis (84 million cases) are the most prevalent NTDs and widely distributed throughout LAC [19] (Table 1), with the largest estimated number of cases in Brazil, Mexico, and Guatemala (Table 4). Guatemala exhibits the highest prevalence of trichuriasis and ascariasis [19], which may partly explain why this nation has the highest prevalence of underweight children [20]; high rates of these two infections also occur along the north Pacific coast of South America, where they are associated with growth stunting [21], as well as in other parts of Central America and the Caribbean [19]. By some estimates, hookworm is the single leading cause of disease burden among the NTDs (Table 2). Of the 50 million cases of hookworm infection that occur in poor rural areas, approximately 65% occur in Brazil (Table 4) [19]. In some regions of Minas Gerais State, Brazil, an estimated 68% of the rural population is infected with hookworm [22], where it is a major cause of anemia in children [23]. High rates of infection also occur in neighboring Paraguay and Peru [19],[21],[24],[25], as well as in parts of Central America and in Suriname [19]. Hookworm is also a major cause of adverse pregnancy outcomes in LAC [25]. Two other STH infections, toxocariasis [26],[27] and strongyloidiasis [28],[29], are also endemic in LAC, but there are no estimates of their regional prevalence.

In 2000, Chitsulo et al. [30] determined that almost all of the estimated 7.3 million cases of schistosomiasis in LAC, caused exclusively by Schistosoma mansoni, occur in Brazil. More recently, Steinmann et al. [31] estimated that there are currently only 1.8 million cases in LAC, with 84% of the cases in Brazil (Table 4). The largest number of cases occurs in the eastern Brazilian states of Minas Gerais and Bahia, as well as in the small neighboring northeastern states of Sergipe, Alagoas, Pernambuco, and Paraiba [32]. In Brazil, there is a high degree of N. americanus and S. mansoni co-infection [22]. Outside of Brazil, S. mansoni infection occurs in the Caribbean, especially in the Dominican Republic and in Venezuela and Suriname [31].

Table 4. Geographic Distribution and Estimated Burden of the Major Helminthiases in LAC.

Currently, four countries—Brazil, Dominican Republic, Guyana, and Haiti—report active transmission of LF and are actively conducting control or elimination efforts through mass drug administration (MDA) [33]. Almost 80% of the LF cases occur in Haiti, where more than 70% of that nation's population is also at risk for infection [20],[33]. In Brazil, LF occurs primarily in the metropolitan areas of Recife (Pernambuco State) and Maceio (Alogoas State) [33]. Through MDA, campaigns to eliminate LF (2.4 million people were treated in 2007) in the Caribbean are in progress [33],[34]. Onchocerciasis is currently endemic in six countries, Brazil, Colombia, Ecuador, Guatemala, Mexico, and Venezuela [35]. Through the Onchocerciasis Elimination Program for the Americas (OEPA), more than 85% of eligible populations in 13 endemic foci have been receiving ivermectin MDA [35]. Foci in Guatemala, southern Mexico, and Venezuela have the highest percentage of the population needing MDA [35]. OEPA has now come close to ending onchocerciasis ocular morbidity in the Americas [35], and has established guidelines in coordination with the WHO for the certification of onchocerciasis elimination [36]. Transmission has been declared interrupted in two foci since 2007, one in Colombia and one in Guatemala.

The major platyhelminth infections in LAC are three zoonoses: cysticercosis, fascioliasis, and paragonimiasis. There are an estimated 400,000 people with symptomatic cysticercosis in LAC [37]. The infection may be eliminatable through better pig husbandry and/or MDA of pigs and humans [37]. Human fascioliasis is an important sheep-associated zoonosis in the Chaco of Bolivia, Paraguay, and Argentina, in the Andean highland region (the Altiplano [38],[39]), and in parts of the Caribbean, including Cuba, Dominican Republic, and Haiti [40],[41]. Paragonimiasis has been reported from Colombia, Ecuador, and Mexico [42], while echinococcosis is another major zoonosis in areas dependent on sheep and other livestock [20].

Protozoan infections.

Chagas disease is one of the highest disease burden NTDs in LAC [43][50]. Almost all of the 8–9 million cases of Chagas disease [43],[44] (with approximately 50,000 new cases annually [44]) occur in poor rural and, increasingly, many new urban and peri-urban areas of Latin America (Table 1). It is estitamed that up to 5.4 million people will develop chronic Chagas heart disease [20],[45], while 900,000 will develop megaesophagus and megacolon [20]. In LAC, the burden of disease caused by Trypanosoma cruzi infection is between five and ten times greater than malaria [46]. Moreover, its economic impact represents a significant percentage of the external debt of the region [46]. Because of the propensity of the kissing bug vector (especially Triatoma infestans) to live in the cracks and crevices and roofs of poor-quality dwellings, and the lack of essential medicines for patients during the acute stages of infection, Chagas disease is disproportionately represented among people living in poverty [12],[46]. Despite successful elimination efforts in the southern cone of South America [50] (for reasons discussed below), the disease remains endemic in many regions of Central and South America [48],[49]. Chagas disease has also emerged or re-emerged in areas of conflict, including Chiapas State, Mexico [47], and Colombia [15]. Increasingly, dogs are recognized as important animal reservoirs of the infection [48]. The major approaches to control include improved case management and vector control programs, together with housing improvement through regional programs, which have been reviewed previously [20], [48][50].

In LAC, both cutaneous and visceral forms of leishmaniasis result primarily from zoonotic transmission from either canine or sylvatic (e.g., opossum, sloth, anteater) reservoir hosts. The most important determinants for the emergence of both new world zoonotic cutaneous leishmaniasis (ZCL) and zoonotic visceral leishmaniasis (ZVL) include poverty, urbanization, and human migration [16]. Leishmania mexicana, L. amazonensis, L. braziliensis, L panamensis, L. peruviana, and L. guyanensis are the major species that cause new world ZCL [51]. Approximately 62,000 cases of ZCL occur primarily in Brazil, Colombia, Paraguay, Venezuela, Panama, Ecuador, and Peru [52] (Table 5), where urbanization near Lutzomyia sandfly breeding sites has led to an increase in the number of cases [53]. In addition, the emergence of ZCL in Colombia is linked to several decades of armed and guerilla internal conflict fueled by cocaine production and trafficking [15]. In northeastern Brazil, ZVL (L. chagasi) has become an important infection in the favelas of Forteleza, Salvador do Bahia, and other urban centers, including Rio de Janeiro and Belo Horizonte [53]. In these impoverished urban and peri-urban settings, the cracked walls and damp earth floors, together with an absence of sanitation and inadequate garbage collection, combine to create sandfly breeding sites [16]. With the exception of Brazil, surveillance systems in Latin America have been limited in their capacity to assess the true burden of ZVL. A regional leishmaniasis control action plan is now being implemented [20].

Table 5. Geographic Distribution and Estimated Burden of Cutaneous Leishmaniasis and Visceral Leishmaniasis in LAC.

Bacterial and fungal infections.

The most important bacterial NTDs are trachoma, leprosy, and some of the bacterial zoonoses, especially leptospirosis. There are approximately 1 million cases of trachoma (ocular Chlamydia trachomitis infection) in Latin America (Table 1), with 97% of the cases in Brazil and the remainder in Guatemala and Mexico [54] (Table 6). Although overall trachoma is not considered a major cause of blindness in LAC [20], the Amazonian region is severely affected, and some indigenous school-aged populations exhibit prevalence as high as 42% [55]. A federal school-based program for the control and antibiotic treatment of trachoma is underway in Brazil. In Central America, trachoma is endemic in focal areas of Guatemala [55], while in Chiapas State, Mexico, the disease is on the verge of elimination [20]. A total of 64,715 cases of leprosy (Mycobacterium leprae) were in treatment in LAC with multi-drug therapy in 2006, with 47,612 new cases detected (Table 1) [56]. Brazil has the largest leprosy disease burden in LAC with 93% of the new cases, and it is the only LAC country that has not yet achieved a goal to eliminate leprosy below the target of one case per 10,000 population [20]. Most of the cases of human brucellosis go undiagnosed or unreported in LAC, while bovine tuberculosis has been eliminated in many regions [20]. Leptospirosis is also an important cause of morbidity in LAC, especially in the favelas of Brazil and other urban slums [10],[57],[58], where it has been linked to a very serious pulmonary hemorrhage syndrome [58]. Bartonellosis remains an important local sandfly-transmitted bacterial infection in the Andean region [59], while cases of Buruli ulcer are reported occasionally in LAC. Several mycoses, such as paracoccidioidomycosis and mycetoma, are responsible for major public health and economic hardships in Latin America; these tend to concentrate around humid forests in subtropical and tropical areas [60],[61].

Table 6. Geographic Distribution and Estimated Burden of the Bacterial NTDs in LAC.

Viral infections.

The most important viral NTDs are dengue and yellow fevers. In 2006, more than one-half million cases of dengue fever (”classic dengue”) (Table 1) were reported, as well as 14,459 cases of dengue hemorrhagic fever (DHF) [62]. Brazil recorded the highest number of cases with 63% of LAC's dengue disease burden (Table 7); however, based on seroprevalence studies, it is believed that the number of reported cases represents only a fraction of the total number [14]. Dengue incidence is on the rise as a consequence of an increasing distribution of the vector Aedes aegypti (as well as a second vector, A. albopictus) as a result of urbanization, increased human migrations and air travel, flooding from global warming, and serious public health lapses in effective vector containment [14]. The increase in cases has been particularly striking during the 1990s and shortly after 2000, when at least 25 countries reported either epidemics or sporadic cases of DHF [14]. American dengue and DHF have a number of unique features compared to dengue in Asia, including its predilection to strike adults and children, its impact on the elderly, and several unusual clinical sequelae, including shock in the absence of hemorrhagic complications [14]. The economic impact of dengue may run into the hundreds of millions of dollars [14]. Through DENGUE-NET, a regional program for epidemiological surveillance coordinated by PAHO and the LAC ministries of health, efforts are in place to improve the reporting of statistical data [20]. Important jungle yellow fever outbreaks have been reported recently, with most of the cases in Peru in 2006 [63], in Brazil in 2007–2008, and in Paraguay and Argentina in 2008 [64],[65]. The observation of apparent urban transmission by A. aegypti in Paraguay in early 2008 would represent the first urban transmission seen in five decades in LAC. As a result, these countries have stepped up community and traveler vaccination campaigns and vector control and implemented a syndromic surveillance system [63], while since 2000, Peru, Bolivia, Paraguay, Colombia, Venezuela, Guyana, and Trinidad and Tobago have incorporated yellow fever vaccine into national child immunization schemes, seeking coverage rates comparable to their current measles vaccination rates [63]. The number of cases of rabies transmitted by dogs to humans continues to decline in LAC, with the majority now being reported from low-income groups living in urban slums of large cities in Bolivia, Brazil, El Salvador, and Haiti [20].

Table 7. Geographic Distribution and Estimated Burden of Reported Dengue Cases in LAC in 2006.

The NTD-Vulnerable Populations: Peoples of Indigenous and African Descent

The NTDs in the Americas are concentrated not only within pockets of intense poverty, but also among selected vulnerable populations, especially some indigenous populations and communities of African descent. In LAC, it is estimated that 7% of the total population and 40% of the rural population belong to a unique ethnic group [20]. Rural poverty disproportionately affects indigenous people, particularly in Bolivia, Colombia, Ecuador, Guatemala, Mexico, and Peru, where 80% of these populations live [9]. In Guatemala and in the neighboring states of southern Mexico, the indigenous populations suffer from some of the highest rates of STH infection in the Americas [19], as well high rates of onchocerciasis [35] and Chagas disease [48]. Some of the indigenous populations acquire their infections in agricultural labor camps and on plantations [9],[66]. Similarly, the indigenous people of Bolivia and Peru experience high rates of fascioliasis, cysticercosis, and plague [20],[39],[67],[68]; those in Colombia are at risk for leishmaniasis, Chagas disease, and yellow fever [15]; and in Brazil, there are several well-documented examples of high levels of STH infection and subsequent growth stunting among indigenous people [69][72], as well as trachoma [55]. Indigenous people also often bear the brunt of vector-borne NTDs that emerge during conflict [15],[48]. In addition to LAC's indigenous communities, poor populations in communities of African descent, such as those found in parts of the Caribbean, Central America, and Brazil, suffer from high prevalence rates of NTDs, especially N. americanus hookworm infection, LF, onchocerciasis, and schistosomiasis. These infections were introduced into the region during the Middle Passage, so that their prevalence among the poor represents a tragic living legacy of the Atlantic slave trade [73].

Past Successes and Current Challenges

There have been some extraordinary successes in both national and regional efforts to take measures for controlling several of the most important NTDs in LAC. First among them has been great progress towards the elimination of LF and onchocerciasis. With respect to the former, Brazil has reduced LF transmission from 11 known foci to one to two small areas, and the at-risk populations in the Caribbean region, particularly in Haiti and Dominican Republic, are receiving MDA [20],[33],[34]. Similarly, all six onchocerciasis-endemic countries have met their full treatment goals and no new ocular disease has been found in recent years; MDA with ivermectin continues in the foci with active transmission [35],[36]. In addition, the prevalence of both trachoma and leprosy has been declining in the region in recent decades [20] and there is optimism that these two ancient scourges could be eliminated in the coming decade. In the Caribbean, the incidence of schistosomiasis has been dramatically reduced [31],[32] and the disease seems potentially eliminatable. Through expanded use of insecticides, improved housing, and other interventions, great gains have been made by Iniciativa de Salud del Cono Sur (INCOSUR) in their efforts to eliminate Chagas disease from South America's southern cone [50]. An exciting new effort to eliminate Chagas disease throughout the region by 2010 has been launched through a new Global Network for Chagas Elimination [43]. Some countries, including Argentina, Belize, Ecuador, Haiti, Honduras, and Nicaragua, have recently initiated major expansions of their STH control programs.

At the same time, enormous challenges to NTD control remain. There is a need to complete elimination efforts for schistosomiasis in the Caribbean [74], and to eliminate the transmission of LF, onchocerciasis, and trachoma in Latin America. Control or elimination of the highest burden NTDs, e.g., Chagas disease, STH infections, and hookworm and schistosomiasis co-infections, still requires intensified efforts. Chagas disease remains one of the region's most devastating NTDs, and even in the southern cone where domestic transmission has been nearly eliminated through vector control of T. infestans, there are concerns about emerging insecticide resistance [48], or the possibility that the vacant niches will be eventually be occupied by other triatomine vectors [50]. In the Chaco, elimination of T. infestans vectors has not been achieved [48],[49], while in Mexico, Central America, the northern tropical regions of South America, and elsewhere, elimination efforts have been thwarted by sylvatic T. dimidiata vectors, which can re-invade dwellings following the use of insecticides [50]. For the case management and treatment of both Chagas disease and leishmaniasis, the major drugs used are either expensive or toxic or both, and frequently require long periods of supervised therapy [50]. There is an urgent need for developing safer anti-Chagas drug regimens and more accurate diagnostic tools to assess the efficacy of anti-trypanosomal drugs, particularly during the chronic phase of the disease [48]. Hookworm infection and other STH infections remain highly prevalent, especially in Brazil, where co-endemic hookworm infection and schistosomiasis (and hookworm and schistosomiasis co-infections) account for large-scale disability and lost economic productivity [22],[23],[75],[76]. Overall, the nation of Brazil accounts for the highest NTD burden in the Americas, and even though Brazil is also the largest country in LAC, its NTD burden is disproportionately high [77]. In addition to high rates of hookworm and schistosomiasis, Brazil also has the greatest number of cases of leishmaniasis, leprosy, and leptospirosis [77]. Also of concern are the five priority NTD-endemic countries, Bolivia, Guyana, Haiti, Honduras, and Nicaragua, targeted by PAHO for accelerated technical cooperation [8].

Approaches to Control or Elimination of the NTDs in LAC

In sub-Saharan Africa an important approach to NTD control relies on the concept of integration and the simultaneous targeting of the most highly prevalent NTDs, i.e., ascariasis, trichuriasis, hookworm infection, schistosomiasis, LF, onchocerciasis, and trachoma, through MDA with a “rapid-impact” package of drugs [1]. In most of LAC, however, the distribution of the NTDs is not as widespread and therefore not always amenable to the same African control strategies. With the exceptions of some areas of eastern Brazil where STH and schistosome infections are also co-endemic with LF (Pernambuco and Alagoas States), and in the Amazonian basin where, particularly among indigenous people, STH infections overlap with onchocerciasis and trachoma (northern Brazil), there are limited opportunities to administer a full rapid-impact package in the Americas. Instead, the pattern of NTD endemicity in the most impoverished areas of LAC has a unique regional character, typically with STH infections or Chagas disease, the most widespread NTDs, co-endemic with a few other NTDs, especially zoonotic NTDs.

As shown in Table 8, at least 11 different sub-regions with unique human and environmental ecologies that promote NTDs have been initially identified in LAC. The regional sociodemographic character of LAC's NTDs include high prevalence in the densely populated and forgotten urban slums and highly concentrated pockets of intense rural poverty characterized by poor or no access to basic services, such as safe water and sanitation, electricity, schooling, and health care, where both human-derived and environmental factors promote NTD transmission. Equally important are the unique geographies of areas such as the dry and cold Altiplano, the dry and barren Chaco, the isolated Central America highlands, and parts of the Amazonian and Caribbean basins, each representing NTD “hot spots” where marginalized and often impoverished populations of indigenous people or people of African descent live in great poverty. For example, some indigenous communities in the Amazonian basin suffer simultaneously from STH infections, onchocerciasis, cutaneous leishmaniasis, scabies, tungiasis, and mycoses. Intense human migrations in the region because of mining, urbanization, deforestation, desertification, and armed conflict represent additional external factors that promote NTD transmission [12],[48],[78],[79].

Table 8. Major NTD Target Sub-Regions and Unique Ecologies.

All of these settings are characterized by poor housing and lack of safe water and basic sanitation as co-factors of transmission. Within such settings, all three major STH infections are nearly ubiquitous among preschool and school-aged children, while hookworm infection is also common in pregnant women. Co-endemic with the STH infections are combinations of one or more of the following NTD infections: schistosomiasis (particularly in eastern Brazil), the vector-borne filarial diseases LF (Caribbean, northeastern Brazil) and onchocerciasis (northern Pacific of South America, Central America, and southern Mexico), leishmaniasis (in all sub-regions except the Caribbean), and other zoonotic NTDs. Similarly, in many of the poorest sub-regions, Chagas disease remains highly endemic. Possibly, for more than any other NTD, the knowledge gaps for Chagas disease remain the greatest, particularly with respect to the extent of zoonotic transmission from dogs and other animals, the emergence and re-emergence of triatomine vectors, the role of bednets, and the lack of specific tools for case management [48]. In addition, the extent of co-infections with Chagas disease and the other major NTDs is not well established. As summarized in Table 9, several different modalities are required to control or eliminate the unique NTDs in these 11 sub-regions, including MDA, targeted administration together with intensified early case detection and management, integrated vector management, control of animal reservoirs, behavioral interventions, and other specialized measures [8].

Countries in the LAC region are exploring different and novel platforms for the integrated delivery of NTD health services, and are synergizing NTD control with other disease control efforts and programs. For example, supported by grants from USAID and the Gates Foundation, Haiti is implementing a pilot project to combine MDA for LF elimination and STH control, while the Honduras Ministry of Health is piloting studies to add deworming for STH control to its maternal and child health, vitamin A delivery, and Chagas disease vector control programs. In the Dominican Republic, the Ministry of Health has successfully integrated MDA into its primary health care system in the southwest region [80]. Similarly, in Nicaragua, deworming is conducted in conjunction with annual nationwide child vaccination campaigns, and in Ecuador multiple partners collaborate to implement deworming of families as a part of a nutritional outreach program targeting the poorest communities. In Argentina, Brazil, Peru, and other countries, in technical collaboration with PAHO, Chagas disease integrated control programs now include blood bank screening, residual insecticide treatment of vector-infested homes, health promotion and education, and community surveillance and reporting of house re-infestation [49], with plans underway to add screening and treatment to prevent congenital Chagas disease transmission. To date, these innovations are relatively new, but it is expected that they will be adopted and scaled in other LAC countries in the coming years.

Future Trends: The Inter-Sectoral Approach for Sustainable NTD Control

In recognition of the severe NTD disease burden in the Americas, the PAHO/WHO, together with the LAC governments, their national disease control programs, the US Centers for Disease Control and Prevention, and the Global Network for Neglected Tropical Diseases [1] will be embarking on efforts to further control, or in some cases, eliminate the region's NTDs. To this end, a strategic plan is being developed, which will be important to MDG targets for health and sustainable poverty reduction in LAC by 2015 [81] (Table 10). The plan uses the existing epidemiological data and adapts an ecosystems approach (Tables 8 and 9) in order to define the most effective interventions that will tackle the multifactoral determinants responsible for the persistence of NTDs, placing health within the context of social and economic development and key MDGs [72].

Table 10. Vision, Goal, Purpose and Scope of a Proposed Strategic Plan Framework for NTD Control.

Rather than a strictly disease-centered approach [4],[9],[72],[82], comprehensive public policies aimed at community development and poverty reduction will be adopted. These policies will be then implemented at the local level through the mobilization and involvement of various agencies [9],[72] under the responsibility of different government sectors (inter-sectoral action) so that they can come together in a synergistic and synchronic manner. Together with strong social participation and appropriate technologies, the inter-sectoral action completes the three pillars advocated in a primary health care strategy and will contribute towards health systems strengthening. Examples of such inter-sectoral partnering were recently reviewed [72],[82]. The collateral benefits of NTD control and elimination also provide multiple entry points for linking diverse programs and projects within the health sector and among different sectors [9],[72],[82], and could build on several PAHO/WHO and World Bank initiatives to combat disease and deprivation [8],[9]. A new generation of control tools, including vaccines, some under development by product development partnerships that include research, development, and manufacturing institutions in LAC, would represent additional innovations to fold into these infrastructures [83]. Among them are new drugs and human vaccines for dengue, hookworm (and hookworm–schistosomiasis co-infections), leishmaniasis, and leprosy [76],[84],[85], as well as transmission-blocking interventions for Chagas disease, cysticercosis, fascioliasis, leptospirosis, and leishmaniasis, which target major animal reservoir hosts [48],[84]. Overall, the control and/or elimination of NTDs represent a highly cost-effective mechanism for providing new investment opportunities in areas currently plagued with these diseases and freeing up their economic potential, i.e., for tourism and ecotourism, ecologically sound mining and oil exploration, infrastructure for rural community transportation, and sustainable crop production (traditional and non-traditional crops). The treatment and prevention of the NTDs have also been revealed as an ethical imperative to respond to the fundamental human right to health [86], particularly for LAC's poorest people, its indigenous populations and people of African descent.


PJH and MEB are supported by the Human Hookworm Vaccine Initiative of the Sabin Vaccine Institute with funding from the Bill & Melinda Gates Foundation. We would like to thank Drs. Simon Brooker (London School of Hygiene and Tropical Medicine) and Jürg Utzinger (Swiss Tropical Institute) for sharing some of their unpublished or Web access data on STH infections and schistosomiasis, respectively. CFP is supported by the Global Health Institute of Emory University and would like to acknowledge the contribution of Dr. Jose Ignacio Santos (Hospital Infantil de México, Federico Gómez), who has contributed to some concepts discussed in this paper. SKA would like to acknowledge the contributions of Drs. John P. Ehrenberg (WHO/WPRO), Patrick Lammie and Mark Eberhard (CDC), and Lorenzo Savioli and his team at the WHO Department of NTDs whose work, visions, ideas, and conversations have contributed to the development of this paper.


  1. 1. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich Sachs S, et al. (2007) Control of neglected tropical diseases. New Eng J Med 357: 1018–1027.
  2. 2. Durrheim DN, Wynd S, Liese B, Gyapong JO (2004) Editorial: Lymphatic filariasis endemicity–an indicator of poverty? Trop Med Int Health 9(8): 843–845. 10.1111/j.1365-3156.2004.01287.x.
  3. 3. Franco-Paredes C, Jones D, Rodriguez-Morales AJ, Santos-Preciado JI (2007) Commentary: Improving the health of neglected populations in latin america. BMC Public Health 7: 11.10.1186/1471-2458-7-11.
  4. 4. The World Bank Group (2008) Regional fact sheet from the World Development Indicators 2008: Latin America and the Caribbean. Available: Accessed 27 August 2008.
  5. 5. Department for International Development (2007) Country profiles: Latin America. Available: Accessed 27 August 2008.
  6. 6. Belizan JM, Cafferata ML, Belizan M, Althabe F (2007) Health inequality in Latin America. Lancet 370(9599): 1599–1600. 10.1016/S0140-6736(07)61673-0.
  7. 7. The World Bank Group (2003) Inequality in Latin America and the Caribbean: breaking with history? Available: Accessed 27 August 2008.
  8. 8. Ault SK (2007) Pan American Health Organization's regional strategic framework for addressing neglected diseases in neglected populations in Latin America and the Caribbean. Mem Inst Oswaldo Cruz 102: Suppl 199–107.
  9. 9. Holveck JC, Ehrenberg JP, Ault SK, Rojas R, Vasquez J, et al. (2007) Prevention, control, and elimination of neglected diseases in the americas: pathways to integrated, inter-programmatic, inter-sectoral action for health and development. BMC Public Health 7: 6. 10.1186/1471-2458-7-6.
  10. 10. Soares LC, Griesinger MO, Dachs JN, Bittner MA, Tavares S (2002) Inequities in access to and use of drinking water services in Latin America and the Caribbean. Rev Panam Salud Publica 11(5–6): 386–396.
  11. 11. Farmer P (2007) Whither equity in health? The state of the poor in Latin America. Cad Saude Publica 23: Suppl 1S7–S12.
  12. 12. Riley LW, Ko AI, Unger A, Reis MG (2007) Slum health: diseases of neglected populations. BMC Int Health Hum Rights 7: 2. 10.1186/1472-698X-7-2.
  13. 13. Pan American Health Organization/World Health Organization (2007) Renewing primary health care in the Americas. Washington (D.C.): Pan American Health Organization. Available: Accessed 27 August 2008.
  14. 14. Torres JR, Castro J (2007) The health and economic impact of dengue in Latin America. Cad Saude Publica 23: Suppl 1S23–S31.
  15. 15. Beyrer C, Villar JC, Suwanvanichkij V, Singh S, Baral SD, et al. (2007) Neglected diseases, civil conflicts, and the right to health. Lancet 370(9587): 619–627. 10.1016/S0140-6736(07)61301-4.
  16. 16. Alvar J, Yactayo S, Bern C (2006) Leishmaniasis and poverty. Trends Parasitol 22(12): 552–557. 10.1016/
  17. 17. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, et al. (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 3: e102.
  18. 18. World Health Organization (2004) World health report 2004: changing history. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002. Annex Table 3. Geneva: World Health Organization. Available: Accessed 27 August 2008.
  19. 19. de Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, et al. (2003) Soil-transmitted helminth infections: Updating the global picture. Trends Parasitol 19(12): 547–551.
  20. 20. Pan American Health Organization (2007) Health in the Americas 2007. Regional, scientific and technical publication 622. Washington (D.C.): Pan American Health Organization.
  21. 21. Casapia M, Joseph SA, Nunez C, Rahme E, Gyorkos TW (2006) Parasite risk factors for stunting in grade 5 students in a community of extreme poverty in Peru. Int J Parasitol 36(7): 741–747. 10.1016/j.ijpara.2006.03.004.
  22. 22. Fleming FM, Brooker S, Geiger SM, Caldas IR, Correa-Oliveira R, et al. (2006) Synergistic associations between hookworm and other helminth species in a rural community in Brazil. Trop Med Int Health 11(1): 56–64. 10.1111/j.1365-3156.2005.01541.x.
  23. 23. Brooker S, Jardim-Botelho A, Quinnell RJ, Geiger SM, Caldas IR, et al. (2007) Age-related changes in hookworm infection, anaemia and iron deficiency in an area of high Necator americanus hookworm transmission in south-eastern Brazil. Trans R Soc Trop Med Hyg 101(2): 146–154. 10.1016/j.trstmh.2006.05.012.
  24. 24. Labiano-Abello N, Canese J, Velazquez ME, Hawdon JM, Wilson ML, et al. (1999) Epidemiology of hookworm infection in Itagua, Paraguay: A cross sectional study. Mem Inst Oswaldo Cruz 94(5): 583–586.
  25. 25. Larocque R, Casapia M, Gotuzzo E, MacLean JD, Soto JC, et al. (2006) A double-blind randomized controlled trial of antenatal mebendazole to reduce low birthweight in a hookworm-endemic area of Peru. Trop Med Int Health 11(10): 1485–1495. 10.1111/j.1365-3156.2006.01706.x.
  26. 26. Chiodo P, Basualdo J, Ciarmela L, Pezzani B, Apezteguia M, et al. (2006) Related factors to human toxocariasis in a rural community of Argentina. Mem Inst Oswaldo Cruz 101(4): 397–400.
  27. 27. Teixeira CR, Chieffi PP, Lescano SA, de Melo Silva EO, Fux B, et al. (2006) Frequency and risk factors for toxocariasis in children from a pediatric outpatient center in southeastern Brazil. Rev Inst Med Trop Sao Paulo 48(5): 251–255.
  28. 28. Silva CV, Ferreira MS, Borges AS, Costa-Cruz JM (2005) Intestinal parasitic infections in HIV/AIDS patients: experience at a teaching hospital in central Brazil. Scand J Infect Dis 37(3): 211–215. 10.1080/00365540410020875.
  29. 29. Yori PP, Kosek M, Gilman RH, Cordova J, Bern C, et al. (2006) Seroepidemiology of strongyloidiasis in the Peruvian Amazon. Am J Trop Med Hyg 74(1): 97–102.
  30. 30. Chitsulo L, Engels D, Montresor A, Savioli L (2000) The global status of schistosomiasis and its control. Acta Trop 77(1): 41–51.
  31. 31. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6(7): 411–425. 10.1016/S1473-3099(06)70521-7.
  32. 32. Amaral RS, Tauil PL, Lima DD, Engels D (2006) An analysis of the impact of the schistosomiasis control programme in Brazil. Mem Inst Oswaldo Cruz 101: Suppl 179–85.
  33. 33. World Health Organization (2006) Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 81(22): 221–232.
  34. 34. Rawlins SC, Lammie P, Tiwari T, Pons P, Chadee DD, et al. (2000) Lymphatic filariasis in the Caribbean region: the opportunity for its elimination and certification. Rev Panam Salud Publica 7(5): 319–324.
  35. 35. World Health Organization (2006) Onchocerciasis (river blindness). Report from the fifteenth InterAmerican conference on onchocerciasis, Caracas, Venezuela. Wkly Epidemiol Rec 81(30): 293–296.
  36. 36. World Health Organization (2007) Meeting of the international task force for disease eradication–11 january 2007. Wkly Epidemiol Rec 82(22/23): 197–202.
  37. 37. Bern C, Garcia HH, Evans C, Gonzalez AE, Verastegui M, et al. (1999) Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 29(5): 1203–1209.
  38. 38. Marcos L, Maco V, Samalvides F, Terashima A, Espinoza JR, et al. (2006) Risk factors for Fasciola hepatica infection in children: a case-control study. Trans R Soc Trop Med Hyg 100(2): 158–166. 10.1016/j.trstmh.2005.05.016.
  39. 39. Parkinson M, O'Neill SM, Dalton JP (2007) Endemic human fasciolosis in the Bolivian altiplano. Epidemiol Infect 135(4): 669–674. 10.1017/S095026880600728X.
  40. 40. Keiser J, Utzinger J (2007) Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 23(11): 555–562. 10.1016/
  41. 41. Blaise J, Raccurt CP (2007) Hepatobiliary fascioliasis and echinococcosis/hydatidosis in domestic animals in Haiti. Rev Sci Tech 26(3): 741–746.
  42. 42. Velez ID, Ortega J, Hurtado MI, Salazar AL, Robledo SM, et al. (2000) Epidemiology of paragonimiasis in Colombia. Trans R Soc Trop Med Hyg 94(6): 661–663.
  43. 43. WHO Expert Committee (2002) Control of Chagas disease. World Health Organ Tech Rep Ser 905: i–vi.1–109, back cover
  44. 44. Senior K (2007) Chagas disease: moving towards global elimination. Lancet Infect Dis 7(9): 572.
  45. 45. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV (2007) Pathogenesis of chronic Chagas heart disease. Circulation 115(9): 1109–1123. 10.1161/CIRCULATIONAHA.106.624296.
  46. 46. Franco-Paredes C, Von A, Hidron A, Rodriguez-Morales AJ, Tellez I, et al. (2007) Chagas disease: an impediment in achieving the millennium development goals in Latin America. BMC Int Health Hum Rights 7: 7. 10.1186/1472-698X-7-7.
  47. 47. Attaran A (2006) Chagas' disease in Mexico. Lancet 368(9549): 1768. discussion 1768–1769. 10.1016/S0140-6736(06)69730-4.
  48. 48. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The challenges of Chagas disease–grim outlook or glimmer of hope. PLoS Med 4(12): e332.
  49. 49. Gurtler RE, Kitron U, Cecere MC, Segura EL, Cohen JE (2007) Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. Proc Natl Acad Sci U S A 104(41): 16194–16199. 10.1073/pnas.0700863104.
  50. 50. Yamagata Y, Nakagawa J (2006) Control of Chagas disease. Adv Parasitol 61: 129–165. 10.1016/S0065-308X(05)61004-4.
  51. 51. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366(9496): 1561–1577. 10.1016/S0140-6736(05)67629-5.
  52. 52. Pan American Health Organization (2008) Leishmaniasis: 2007 update. Available: Accessed 27 August 2008.
  53. 53. World Health Organization (2002) Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol Rec 77(44): 365–370.
  54. 54. World Health Organization (2007) Global health atlas. Available: Accessed 2 March 2008.
  55. 55. Munoz B, West SK (2002) Blindness and visual impairment in the Americas and the Caribbean. Br J Ophthalmol 86(5): 498–504.
  56. 56. Pan American Health Organization (2008) Situation report: leprosy in the Americas, 2007. 11 p. Available: Accessed 29 August 2008.
  57. 57. Sarkar U, Nascimento SF, Barbosa R, Martins R, Nuevo H, et al. (2002) Population-based case-control investigation of risk factors for leptospirosis during an urban epidemic. Am J Trop Med Hyg 66(5): 605–610.
  58. 58. Segura ER, Ganoza CA, Campos K, Ricaldi JN, Torres S, et al. (2005) Clinical spectrum of pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral burden. Clin Infect Dis 40(3): 343–351. 10.1086/427110.
  59. 59. Maguina C, Garcia PJ, Gotuzzo E, Cordero L, Spach DH (2001) Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis 33(6): 772–779.
  60. 60. Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, Colombo AL, Moretti ML (2006) Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop 39(3): 297–310.
  61. 61. Ahmed AO, van Leeuwen W, Fahal A, van de Sande W, Verbrugh H, et al. (2004) Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis 4(9): 566–574. 10.1016/S1473-3099(04)01131-4.
  62. 62. Pan American Health Organization. 2006: number of reported cases of dengue & dengue hemorrhagic fever (DHF), region of the americas (by country and subregion). 2007(November 15)Available: via the Internet.
  63. 63. World Health Organization (2008) Yellow fever in Africa and South America, 2006. Wkly Epidemiol Rec 83: 69-76. Available: Accessed 27 August 2008.
  64. 64. Pan American Health Organization (2008) Update on jungle yellow fever (JYF) in Brazil, Paraguay, and Argentina [press release]. Available: Accessed 27 August 2008.
  65. 65. World Health Organization (2008) Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec 83(12): 105.
  66. 66. Rodriguez-Perez MA, Cabrera AS, Ortega CL, Basanez MG, Davies JB (2007) Contribution of migrant coffee labourers infected with onchocerca volvulus to the maintenance of the microfilarial reservoir in an ivermectin-treated area of Mexico. Filaria J 6: 16. 10.1186/1475-2883-6-16.
  67. 67. Carrique-Mas J, Iihoshi N, Widdowson MA, Roca Y, Morales G, et al. (2001) An epidemiological study of Taenia solium cysticercosis in a rural population in the Bolivian Chaco. Acta Trop 80(3): 229–235.
  68. 68. Valero MA, Mas-Coma S (2000) Comparative infectivity of Fasciola hepatica metacercariae from isolates of the main and secondary reservoir animal host species in the Bolivian Altiplano high human endemic region. Folia Parasitol (Praha) 47(1): 17–22.
  69. 69. Beltrame A, Scolari C, Torti C, Urbani C (2002) Soil transmitted helminth (STH) infections in an indigenous community in Ortigueira, Parana, Brazil and relationship with its nutritional status. Parassitologia 44(3–4): 137–139.
  70. 70. Fontbonne A, Freese-De-Carvalho E, Acioli MD, Sa GA, Cesse EA (2001) Risk factors for multiple intestinal parasites in an indigenous community of the state of Pernambuco, Brazil. Cad Saude Publica 17(2): 367–373.
  71. 71. Scolari C, Torti C, Beltrame A, Matteelli A, Castelli F, et al. (2000) Prevalence and distribution of soil-transmitted helminth (STH) infections in urban and indigenous schoolchildren in Ortigueira, state of Parana, Brasil: implications for control. Trop Med Int Health 5(4): 302–307.
  72. 72. Ehrenberg JP, Ault SK (2005) Neglected diseases of neglected populations: thinking to reshape the determinants of health in Latin America and the Caribbean. BMC Public Health 5: 119. 10.1186/1471-2458-5-119.
  73. 73. Lammie PJ, Lindo JF, Secor WE, Vasquez J, Ault SK, et al. (2007) Eliminating lymphatic filariasis, onchocerciasis, and schistosomiasis from the Americas: breaking a historical legacy of slavery. PLoS Negl Trop Dis 1(2): e71.
  74. 74. Hotez PJ (2008) Holidays in the sun and the Caribbean's forgotten burden of neglected tropical diseases. PLoS Negl Trop Dis 2(5): e239.
  75. 75. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, et al. (2006) Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 367(9521): 1521–1532. 10.1016/S0140-6736(06)68653-4.
  76. 76. Diemert DJ, Bethony JM, Hotez PJ (2008) Hookworm vaccines. Clin Infect Dis 46(2): 282–288. 10.1086/524070.
  77. 77. Hotez PJ (2008) The giant anteater in the room: Brazil's neglected tropical diseases problem. PLoS Negl Trop Dis 2(1): e177.
  78. 78. Vittor AY, Gilman RH, Tielsch J, Glass G, Shields T, et al. (2006) The effect of deforestation on the human-biting rate of Anopheles darlingi, the primary vector of Falciparum malaria in the Peruvian Amazon. Am J Trop Med Hyg 74(1): 3–11.
  79. 79. Vosti SA (1990) Malaria among gold miners in southern Para, Brazil: estimates of determinants and individual costs. Soc Sci Med 30(10): 1097–1105.
  80. 80. Baker MC, McFarland DA, Gonzales M, Diaz MJ, Molyneux DH (2007) The impact of integrating the elimination programme for lymphatic filariasis into primary health care in the Dominican Republic. Int J Health Plann Manage 22(4): 337–352. 10.1002/hpm.900.
  81. 81. Pan American Health Organization (2007) Health agenda for the Americas 2008–2017. 34 p. Available: Accessed 27 August 2008.
  82. 82. Ault SK (2008) Intersectoral approaches to neglected diseases. Ann N Y Acad Sci 1136: 64–69. 10.1196/annals.1425.033.
  83. 83. Morel CM, Acharya T, Broun D, Dangi A, Elias C, et al. (2005) Health innovation networks to help developing countries address neglected diseases. Science 309(5733): 401–404. 10.1126/science.1115538.
  84. 84. Hotez PJ, Ferris MT (2006) The antipoverty vaccines. Vaccine 24: 5787–5799.
  85. 85. Hotez PJ, Bethony J, Costa Oliveira S, Brindley PJ, Loukas A (2008) Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 7(6): 745–752.
  86. 86. Hunt P (2006) The human right to the highest attainable standard of health: new opportunities and challenges. Trans R Soc Trop Med Hyg 100(7): 603–607. 10.1016/j.trstmh.2006.03.001.